StockNews.AI
APM
StockNews.AI
10 days

Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

1. Aptorum Group received a Nasdaq non-compliance notification for bid price. 2. They have 180 days to regain compliance before facing delisting. 3. A reverse stock split is a potential option to restore compliance. 4. The notification does not immediately impact trading or listing. 5. Commitment to maintaining Nasdaq listing is emphasized.

3 mins saved
Full Article

FAQ

Why Bearish?

The notification of non-compliance may raise investor concerns about APM's stability, affecting its price. Historical cases show stocks often suffer when delisting threats arise, e.g., Nasdaq-listed companies saw declines after similar notifications.

How important is it?

The non-compliance notification is crucial for APM, indicating potential stock delisting. This issue affects investor sentiment and stock price significantly due to market perceptions of instability.

Why Short Term?

The urgency of the 180-day compliance period suggests immediate investor scrutiny and consequent price volatility. Companies typically experience price drops during similar grace periods without prompt corrective actions.

Related Companies

April 16, 2025 12:27 ET  | Source: Aptorum Group Ltd Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2). The notification does not immediately affect the listing or trading of the company’s shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until 14 October 2025, to regain compliance with the continued listing requirements. During this period, Aptorum Group Limited intends to evaluate all available options to restore compliance, including, if necessary, a reverse stock split. The company is committed to maintaining its Nasdaq listing and will take all reasonable measures to achieve compliance within the stipulated time frame. About Aptorum Group Limited Aptorum Group Limited is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. Forward-Looking Statements This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the company’s current expectations and projections about future events and are based on assumptions. Actual results may differ materially from those projected. For further information, please contact: investor.relations@aptorumgroup.com

Related News